128 related articles for article (PubMed ID: 20653104)
21. Selection of an adjuvant for vaccination with the malaria antigen, MSA-2.
Pye D; Vandenberg KL; Dyer SL; Irving DO; Goss NH; Woodrow GC; Saul A; Alving CR; Richards RL; Ballou WR; Wu MJ; Skoff K; Anders RF
Vaccine; 1997 Jun; 15(9):1017-23. PubMed ID: 9261951
[TBL] [Abstract][Full Text] [Related]
22. Stability and potency of the Plasmodium falciparum MSP1-19/AMA-1(III) chimeric vaccine candidate with Montanide ISA720 adjuvant.
Xue X; Ding F; Zhang Q; Pan X; Qu L; Pan W
Vaccine; 2010 Apr; 28(18):3152-8. PubMed ID: 20197139
[TBL] [Abstract][Full Text] [Related]
23. Comparison of the adjuvanticity of two different delivery systems on the induction of humoral and cellular responses to synthetic peptides.
Mata E; Igartua M; Hernández RM; Rosas JE; Patarroyo ME; Pedraz JL
Drug Deliv; 2010; 17(7):490-9. PubMed ID: 20500129
[TBL] [Abstract][Full Text] [Related]
24. Immunogenicity and in vitro protective efficacy of a polyepitope Plasmodium falciparum candidate vaccine constructed by epitope shuffling.
Cai Q; Peng G; Bu L; Lin Y; Zhang L; Lustigmen S; Wang H
Vaccine; 2007 Jul; 25(28):5155-65. PubMed ID: 17548134
[TBL] [Abstract][Full Text] [Related]
25. A human phase 1 vaccine clinical trial of the Plasmodium falciparum malaria vaccine candidate apical membrane antigen 1 in Montanide ISA720 adjuvant.
Saul A; Lawrence G; Allworth A; Elliott S; Anderson K; Rzepczyk C; Martin LB; Taylor D; Eisen DP; Irving DO; Pye D; Crewther PE; Hodder AN; Murphy VJ; Anders RF
Vaccine; 2005 Apr; 23(23):3076-83. PubMed ID: 15811655
[TBL] [Abstract][Full Text] [Related]
26. Long-lasting protective immune response to the 19-kilodalton carboxy-terminal fragment of Plasmodium yoelii merozoite surface protein 1 in mice.
Jeamwattanalert P; Mahakunkijcharoen Y; Kittigul L; Mahannop P; Pichyangkul S; Hirunpetcharat C
Clin Vaccine Immunol; 2007 Apr; 14(4):342-7. PubMed ID: 17314232
[TBL] [Abstract][Full Text] [Related]
27. Immunomodulatory activity of novel adjuvant formulations based on Montanide ISA oil-based adjuvants and peptidoglycan monomer.
Habjanec L; Halassy B; Tomasić J
Int Immunopharmacol; 2008 May; 8(5):717-24. PubMed ID: 18387514
[TBL] [Abstract][Full Text] [Related]
28. Phase I safety and immunogenicity trial of Plasmodium vivax CS derived long synthetic peptides adjuvanted with montanide ISA 720 or montanide ISA 51.
Herrera S; Fernández OL; Vera O; Cárdenas W; Ramírez O; Palacios R; Chen-Mok M; Corradin G; Arévalo-Herrera M
Am J Trop Med Hyg; 2011 Feb; 84(2 Suppl):12-20. PubMed ID: 21292873
[TBL] [Abstract][Full Text] [Related]
29. Effects on immunogenicity by formulations of emulsion-based adjuvants for malaria vaccines.
Fox CB; Baldwin SL; Vedvick TS; Angov E; Reed SG
Clin Vaccine Immunol; 2012 Oct; 19(10):1633-40. PubMed ID: 22896687
[TBL] [Abstract][Full Text] [Related]
30. Vaccination with recombinant Plasmodium vivax MSP-10 formulated in different adjuvants induces strong immunogenicity but no protection.
Giraldo MA; Arevalo-Pinzon G; Rojas-Caraballo J; Mongui A; Rodriguez R; Patarroyo MA
Vaccine; 2009 Dec; 28(1):7-13. PubMed ID: 19782110
[TBL] [Abstract][Full Text] [Related]
31. A malaria vaccine that elicits in humans antibodies able to kill Plasmodium falciparum.
Druilhe P; Spertini F; Soesoe D; Corradin G; Mejia P; Singh S; Audran R; Bouzidi A; Oeuvray C; Roussilhon C
PLoS Med; 2005 Nov; 2(11):e344. PubMed ID: 16262450
[TBL] [Abstract][Full Text] [Related]
32. Preclinical evaluation of a synthetic Plasmodium falciparum MAP malaria vaccine in Aotus monkeys and mice.
Moreno CA; Rodriguez R; Oliveira GA; Ferreira V; Nussenzweig RS; Moya Castro ZR; Calvo-Calle JM; Nardin E
Vaccine; 1999 Aug; 18(1-2):89-99. PubMed ID: 10501239
[TBL] [Abstract][Full Text] [Related]
33. AFCo1, a meningococcal B-derived cochleate adjuvant, strongly enhances antibody and T-cell immunity against Plasmodium falciparum merozoite surface protein 4 and 5.
Bracho G; Zayas C; Wang L; Coppel R; Pérez O; Petrovsky N
Malar J; 2009 Feb; 8():35. PubMed ID: 19250541
[TBL] [Abstract][Full Text] [Related]
34. In interleukin-4-deficient mice, alum not only generates T helper 1 responses equivalent to freund's complete adjuvant, but continues to induce T helper 2 cytokine production.
Brewer JM; Conacher M; Satoskar A; Bluethmann H; Alexander J
Eur J Immunol; 1996 Sep; 26(9):2062-6. PubMed ID: 8814247
[TBL] [Abstract][Full Text] [Related]
35. The non-toxic and biodegradable adjuvant Montanide ISA 720/CpG can replace Freund's in a cancer vaccine targeting ED-B--a prerequisite for clinical development.
Huijbers EJ; Femel J; Andersson K; Björkelund H; Hellman L; Olsson AK
Vaccine; 2012 Jan; 30(2):225-30. PubMed ID: 22079080
[TBL] [Abstract][Full Text] [Related]
36. Human phase I vaccine trials of 3 recombinant asexual stage malaria antigens with Montanide ISA720 adjuvant.
Saul A; Lawrence G; Smillie A; Rzepczyk CM; Reed C; Taylor D; Anderson K; Stowers A; Kemp R; Allworth A; Anders RF; Brown GV; Pye D; Schoofs P; Irving DO; Dyer SL; Woodrow GC; Briggs WR; Reber R; Stürchler D
Vaccine; 1999 Aug; 17(23-24):3145-59. PubMed ID: 10462251
[TBL] [Abstract][Full Text] [Related]
37. Immunogenicity and protective efficacy of Escherichia coli expressed Plasmodium falciparum merozoite surface protein-1(42) using human compatible adjuvants.
Sachdeva S; Mohmmed A; Dasaradhi PV; Crabb BS; Katyal A; Malhotra P; Chauhan VS
Vaccine; 2006 Mar; 24(12):2007-16. PubMed ID: 16377036
[TBL] [Abstract][Full Text] [Related]
38. Comparing Montanide ISA 720 and 50-V2 adjuvants formulated with LmSTI1 protein of Leishmania major indicated the potential cytokine patterns for induction of protective immune responses in BALB/c mice.
Shokri M; Roohvand F; Alimohammadian MH; Ebrahimirad M; Ajdary S
Mol Immunol; 2016 Aug; 76():108-15. PubMed ID: 27428863
[TBL] [Abstract][Full Text] [Related]
39. A recombinant vaccine based on domain II of Plasmodium vivax Apical Membrane Antigen 1 induces high antibody titres in mice.
Gentil F; Bargieri DY; Leite JA; Françoso KS; Patricio MB; Espíndola NM; Vaz AJ; Palatnik-de-Sousa CB; Rodrigues MM; Costa FT; Soares IS
Vaccine; 2010 Aug; 28(38):6183-90. PubMed ID: 20654667
[TBL] [Abstract][Full Text] [Related]
40. Immunogenic properties of a recombinant fusion protein containing the C-terminal 19 kDa of Plasmodium falciparum merozoite surface protein-1 and the innate immunity agonist FliC flagellin of Salmonella typhimurium.
Bargieri DY; Leite JA; Lopes SC; Sbrogio-Almeida ME; Braga CJ; Ferreira LC; Soares IS; Costa FT; Rodrigues MM
Vaccine; 2010 Apr; 28(16):2818-26. PubMed ID: 20170765
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
